HK1193823A1 - 用於治療癌症的作為 -激酶抑制劑的苯並吡喃酮化合物 - Google Patents
用於治療癌症的作為 -激酶抑制劑的苯並吡喃酮化合物Info
- Publication number
- HK1193823A1 HK1193823A1 HK14107290.6A HK14107290A HK1193823A1 HK 1193823 A1 HK1193823 A1 HK 1193823A1 HK 14107290 A HK14107290 A HK 14107290A HK 1193823 A1 HK1193823 A1 HK 1193823A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- treatment
- kinase inhibitors
- chromenone compounds
- chromenone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290187 | 2011-04-13 | ||
| PCT/GB2012/050793 WO2012140419A1 (en) | 2011-04-13 | 2012-04-12 | Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1193823A1 true HK1193823A1 (zh) | 2014-10-03 |
Family
ID=46017999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14107290.6A HK1193823A1 (zh) | 2011-04-13 | 2014-07-17 | 用於治療癌症的作為 -激酶抑制劑的苯並吡喃酮化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8530470B2 (zh) |
| EP (1) | EP2697220B1 (zh) |
| JP (1) | JP5937674B2 (zh) |
| KR (1) | KR101854950B1 (zh) |
| CN (1) | CN103596948B (zh) |
| AR (1) | AR086100A1 (zh) |
| AU (1) | AU2012241594B2 (zh) |
| BR (1) | BR112013026397A2 (zh) |
| CA (1) | CA2832787A1 (zh) |
| ES (1) | ES2565384T3 (zh) |
| HK (1) | HK1193823A1 (zh) |
| MX (1) | MX340300B (zh) |
| RU (1) | RU2598028C2 (zh) |
| UY (1) | UY34013A (zh) |
| WO (1) | WO2012140419A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9949979B2 (en) | 2011-12-15 | 2018-04-24 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| EP2653464B1 (en) | 2012-04-20 | 2017-09-27 | Rohm and Haas Company | Benzylamine hydrophobe |
| CN111904962A (zh) | 2012-11-08 | 2020-11-10 | 理森制药股份公司 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
| JPWO2015146561A1 (ja) * | 2014-03-26 | 2017-04-13 | 住友精化株式会社 | 臭化芳香族エステル化合物の製造方法 |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| BR112018007068B1 (pt) * | 2015-10-09 | 2024-01-02 | Janssen Pharmaceutica N.V. | Derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta, seu uso e composição farmacêutica que os compreende |
| WO2017090002A2 (en) * | 2015-11-27 | 2017-06-01 | Gvk Biosciences Private Limited | Inhibitors of pi3 kinases |
| RU2612875C1 (ru) * | 2015-12-14 | 2017-03-13 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Средство для ингибирования фермента тирозил-днк-фосфодиэстеразы 1 человека |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| RU2764522C1 (ru) * | 2021-05-25 | 2022-01-18 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | 3,3'[(гексано-1,6-диилбис(азанедиил)]бис-(7-гидрокси-6-метоксикарбонил-2-оксо-2H-хромен), обладающий антибактериальной активностью |
| CN113717138B (zh) * | 2021-10-21 | 2023-02-24 | 沈阳药科大学 | 一类氮芥类色原酮衍生物与应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU634994B2 (en) | 1988-12-21 | 1993-03-11 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| ATE482946T1 (de) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| NZ538420A (en) | 2002-08-16 | 2007-06-29 | Kinacia Pty Ltd | Inhibition of phosphoinositide 3-kinase beta |
| CN100430389C (zh) * | 2002-08-16 | 2008-11-05 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| RU2006124421A (ru) | 2003-12-09 | 2008-01-20 | ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) | Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| ES2491140T3 (es) * | 2006-06-21 | 2014-09-05 | Piramal Enterprises Limited | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2012
- 2012-04-11 UY UY0001034013A patent/UY34013A/es not_active Application Discontinuation
- 2012-04-11 US US13/444,221 patent/US8530470B2/en not_active Expired - Fee Related
- 2012-04-12 AU AU2012241594A patent/AU2012241594B2/en not_active Ceased
- 2012-04-12 BR BR112013026397A patent/BR112013026397A2/pt not_active Application Discontinuation
- 2012-04-12 RU RU2013147736/04A patent/RU2598028C2/ru not_active IP Right Cessation
- 2012-04-12 JP JP2014504388A patent/JP5937674B2/ja not_active Expired - Fee Related
- 2012-04-12 ES ES12717456.3T patent/ES2565384T3/es active Active
- 2012-04-12 WO PCT/GB2012/050793 patent/WO2012140419A1/en active Application Filing
- 2012-04-12 CN CN201280028758.5A patent/CN103596948B/zh not_active Expired - Fee Related
- 2012-04-12 CA CA2832787A patent/CA2832787A1/en not_active Abandoned
- 2012-04-12 EP EP12717456.3A patent/EP2697220B1/en not_active Not-in-force
- 2012-04-12 KR KR1020137029759A patent/KR101854950B1/ko active IP Right Grant
- 2012-04-12 MX MX2013011931A patent/MX340300B/es active IP Right Grant
- 2012-04-13 AR ARP120101290A patent/AR086100A1/es not_active Application Discontinuation
-
2013
- 2013-08-06 US US13/960,191 patent/US20140038937A1/en not_active Abandoned
-
2014
- 2014-07-17 HK HK14107290.6A patent/HK1193823A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013011931A (es) | 2014-03-27 |
| US8530470B2 (en) | 2013-09-10 |
| KR101854950B1 (ko) | 2018-05-04 |
| CN103596948A (zh) | 2014-02-19 |
| US20140038937A1 (en) | 2014-02-06 |
| RU2598028C2 (ru) | 2016-09-20 |
| MX340300B (es) | 2016-07-05 |
| JP5937674B2 (ja) | 2016-06-22 |
| AR086100A1 (es) | 2013-11-20 |
| AU2012241594B2 (en) | 2016-03-10 |
| ES2565384T3 (es) | 2016-04-04 |
| EP2697220A1 (en) | 2014-02-19 |
| UY34013A (es) | 2012-11-30 |
| US20120264731A1 (en) | 2012-10-18 |
| AU2012241594A1 (en) | 2013-10-17 |
| CA2832787A1 (en) | 2012-10-18 |
| BR112013026397A2 (pt) | 2017-09-12 |
| JP2014510779A (ja) | 2014-05-01 |
| KR20140027985A (ko) | 2014-03-07 |
| CN103596948B (zh) | 2016-04-27 |
| RU2013147736A (ru) | 2015-05-20 |
| EP2697220B1 (en) | 2016-01-13 |
| WO2012140419A1 (en) | 2012-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1193823A1 (zh) | 用於治療癌症的作為 -激酶抑制劑的苯並吡喃酮化合物 | |
| HK1232158A1 (zh) | 用於治療肝癌的藥物 | |
| HK1207861A1 (zh) | 作為 抑制劑的用於治療癌症的取代的環烯並吡唑 | |
| IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
| HRP20150692T8 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
| PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
| EP2542081A4 (en) | COMPOSITIONS FOR CANCER TREATMENT | |
| HK1201256A1 (zh) | 用於治療癌症的吡咯並嘧啶化合物 | |
| IL232530B (en) | A combination of factors for cancer treatment | |
| PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| HUE045461T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| EP2788378A4 (en) | ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER | |
| HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
| EP2608671A4 (en) | COMPOUNDS USED IN THE TREATMENT OF CANCER | |
| IL221404A (en) | Inhibits thiogenethone-based autophagy based on cancer therapy | |
| SG10201502566SA (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| IL275636A (en) | Medical combination for cancer treatment | |
| IL238592B (en) | Compounds for the treatment of liver diseases | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| GB201012845D0 (en) | Inhibition of dicer function for treatment of cancer | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP2768512A4 (en) | ENZYME HAMMER FOR CANCER TREATMENT | |
| GB201214877D0 (en) | Compounds for treatments of tumors | |
| IL227688B (en) | History of aminostatin as cathepsin d inhibitors for the treatment of osteoarthritis | |
| IL215199A0 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200410 |